FDA Intelligence | FDA

Advertising and Promotion

Jul 15, 2023
Latest Untitled Letter Indicates OPDP Wants Most Important Risk Info Presented Upfront and Prominently
Jun 29, 2023
Congressional Appropriation Committees Take Interest in Drug Marketing
Jun 3, 2023
OPDP Marks One Year Since Last Enforcement Letter
May 4, 2023
AI-Composed Communications Pose Concerns for Industry and FDA
Mar 28, 2023
Misinformation Pandemic Poses Major Challenges for Regulators and Regulated
Mar 7, 2023
New Option for Marketing Concerns Emerges
Jan 30, 2023
Aduhelm Marketing Plan Raises Issues About Targeted Audiences
Jan 3, 2023
Stability and Status Quo Predicted for Ad Promo in 2023
Dec 8, 2022
Risk Minimization Is Still OPDP’s Top Concern in 2022 Enforcement Letters
Nov 11, 2022
Medical Product Advertisers Need To Separate Themselves From Misinformation Purveyors

Good Clinical Practice

Food Labeling

FDA Regulation & Enforcement

Medical Devices

Copyright © Thompson FDA, a division of CBIS. All rights reserved.